Page 39 - Lockup News Today : Breaking News, Live Updates & Top Stories | Vimarsana

IPO Lockup Expiration Alert: Pandion Therapeutics (PAND) Pandion Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for patients suffering from autoimmune diseases. The company's lead product candidate is PT101, for which a phase 1a/2b clinical trial in ulcerative colitis is expected to start in mid-2021 and phase II clinical trial in systemic lupus erythematosus is expected to start in the second half 2021. Also in the pipeline are a couple of compounds in pre-clinical testing like PT627 for the treatment of autoimmune disease, and PT002 and PT001, for t...

IPO Lockup Expiration Alert: ALX Oncology Holdings Inc. (ALXO) BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - The lockup period of Burlingame, California-based ALX Oncology Holdings Inc. (ALXO) ends on January 13. ALX Oncology Holdings is a clinical-stage immuno-oncology company developing therapies targeting CD47 checkpoint pathway for blood and solid tumor cancers. The company's lead product candidate is ALX148, a next-generation CD47 blocking therapeutic, which is being studied across a variety of cancers. 2021 is expected to be another productive year with additional clinical trial initiations and ...

IPO Lockup Expiration Alert: Nkarta Inc. (NKTX) BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - The lockup period of Nkarta Inc. (NKTX) expires tomorrow, i.e. on Jan 6. South San Francisco, California-based Nkarta Inc. is a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer. There are two product candidates in the pipeline - NKX101 and NKX019. NKX101 is under a phase I trial for the treatment of relapsed/refractory acute myeloid leukemia (AML) or higher risk myelodysplastic syndromes (MDS). The first patient in this trial was treated as recently as Novemb...

IPO Lockup Expiration Alert: Inventiva SA (IVA) BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - The lockup period of Inventiva SA (IVA) ends on January 6. Daix, France-based Inventiva is a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, mucopolysaccharidoses, or MPS, and other diseases. The company's lead drug candidate Lanifibranor for the treatment of non-alcoholic steatohepatitis (NASH), which successfully completed a phase IIb study last June, carries the FDA's Breakthrough Therapy tag. A pivotal phase II...

IPO Lockup Expiration Alert: Poseida Therapeutics (PSTX) BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - The lockup period of Poseida Therapeutics (PSTX) ends tomorrow, i.e., January 6. San Diego, California-based Poseida Therapeutics is a clinical-stage biopharmaceutical company developing cell and gene therapies to treat a range of cancers. The company's pipeline includes P-PSMA-101, a solid tumor autologous CAR-T product candidate being developed to treat patients with metastatic castrate resistant prostate cancer; P-BCMA-101, an autologous CAR-T product candidate for the treatment of patients with r...